Merck-Kelun lung cancer drug cut tumor progression risk by 65%

A groundbreaking study conducted in China has revealed promising results for a new type of targeted chemotherapy developed by Kelun-Biotech and licensed to Merck. The drug, sacituzumab tirumotecan (sac-TMT), showed a remarkable 65% reduction in the risk of tumor progression in patients with lung cancer. Additionally, preliminary data from the Phase 3 trial indicated a potential survival benefit for patients receiving the innovative treatment.

This study marks a significant milestone in the field of oncology as it is the first successful combination of an antibody-drug conjugate with a PD-1-targeted immunotherapy in patients with advanced non-small cell lung cancer who have not received prior treatment. The collaboration between Kelun-Biotech and Merck has resulted in a promising treatment option for patients facing this devastating disease.

While the initial results are encouraging, further follow-up is needed to confirm the long-term benefits of sac-TMT in lung cancer patients. The potential for this new chemotherapy to improve outcomes for patients with advanced non-small cell lung cancer is significant and could have a profound impact on the standard of care for this patient population.

For more in-depth coverage and analysis of this groundbreaking study and other developments in the biotech sector, consider subscribing to STAT+. By unlocking exclusive content and daily updates, subscribers gain access to valuable insights and information that can help shape the future of healthcare and drug development.

Stay informed and stay ahead of the curve with STAT+ subscription. Subscribe now to access this article and much more.